Abstract
Aim: To evaluate the effect of functional polymorphisms (rs4354668 and rs2731880) of the excitatory amino acid transporters (EAAT1 and 2) on the cognitive dysfunction that characterizes schizophrenia. Materials & methods: One hundred and ninety two subjects diagnosed with schizophrenia were assessed with Brief Assessment of Cognition in Schizophrenia, Wisconsin Card Sorting Test, Continuous Performance Test and N-back test and genotyped for rs4354668 and rs2731880. Results: ANOVA showed a significant difference among both EAAT1 and EAAT2 genotype groups on different cognitive measures. Worse performances were observed among carriers of the genotypes associated with lower EAAT expression. Conclusion: Results suggest that impaired activity and EAAT expression could influence cognitive performances in schizophrenia, thus representing a target of interest for development of pharmacological strategies aimed to improve cognition.
Original language | English |
---|---|
Pages (from-to) | 925-932 |
Number of pages | 8 |
Journal | Pharmacogenomics |
Volume | 15 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2014 |
Keywords
- cognitive impairment
- EAAT1
- EAAT2
- glutamate uptake
- schizophrenia
ASJC Scopus subject areas
- Pharmacology
- Genetics
- Molecular Medicine
- Medicine(all)